Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Deffered Revenue: 2019-2021

Historic Non-Current Deffered Revenue for Revolution Medicines (RVMD) over the last 3 years, with Dec 2021 value amounting to $6.6 million.

  • Revolution Medicines' Non-Current Deffered Revenue fell 44.02% to $5.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.4 million, marking a year-over-year decrease of 44.02%. This contributed to the annual value of $6.6 million for FY2021, which is 22.50% down from last year.
  • Latest data reveals that Revolution Medicines reported Non-Current Deffered Revenue of $6.6 million as of FY2021, which was down 22.50% from $8.5 million recorded in FY2020.
  • Revolution Medicines' Non-Current Deffered Revenue's 5-year high stood at $14.7 million during FY2019, with a 5-year trough of $6.6 million in FY2021.
  • For the 3-year period, Revolution Medicines' Non-Current Deffered Revenue averaged around $9.9 million, with its median value being $8.5 million (2020).
  • Data for Revolution Medicines' Non-Current Deffered Revenue shows a maximum YoY tumbled of 42.41% (in 2020) over the last 5 years.
  • Revolution Medicines' Non-Current Deffered Revenue (Yearly) stood at $14.7 million in 2019, then plummeted by 42.41% to $8.5 million in 2020, then dropped by 22.50% to $6.6 million in 2021.